文献速递其他结缔组织病

包涵体肌炎临床试验中安慰剂反应的系统综述与荟萃分析

A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该系统综述与荟萃分析纳入11项随机双盲安慰剂对照试验、共257例接受安慰剂的包涵体肌炎患者,评估其肌力与包涵体肌炎功能评定量表(IBMFRS)的变化。接受安慰剂者肌力平均效应量为-0.398(95%CI -0.652,-0.144),每变化一周标准化均数差(SMD)为-0.009(-0.016,-0.002);12个月时IBMFRS合并变化为-2.189分(-3.893,-0.485)。作者认为这些估计值可用于未来研究的样本量计算。

要点

  • 11项试验共257例接受安慰剂的包涵体肌炎患者,肌力出现可测量的下降。
  • 安慰剂组肌力平均效应量为-0.398(95%CI -0.652,-0.144),P=0.002。
  • 12个月时IBMFRS合并变化为-2.189分(95%CI -3.893,-0.485),P=0.012。

核心结论

  • 包涵体肌炎患者在临床试验期间接受安慰剂时,肌力和IBMFRS出现可测量的下降,符合该病缓慢进展的特点。
  • 作者认为这些估计值可用于未来研究的样本量计算。

研究设计与样本

  • 系统综述与荟萃分析,检索多个数据库,纳入对安慰剂组不施加治疗干预的随机双盲安慰剂对照试验。
  • 共纳入11项符合条件的试验,257例接受安慰剂的参与者,偏倚风险按Cochrane协作网偏倚风险2(RoB2)工具评估为低。
  • 采用DerSimonian-Laird连续随机效应模型计算合并效应,肌力变化用标准化均数差(SMD),IBMFRS用均数差,并用荟萃回归分析肌力变化。
  • 异质性用I2指标评估。

主要发现

  • 接受安慰剂者肌力平均效应量为-0.398(95%CI -0.652,-0.144)(P=0.002)。
  • SMD每周变化-0.009(-0.016,-0.002)分(P=0.015)。
  • 徒手肌力测试的异质性较高(I2=67.68%),定量肌力测试的异质性为0%。
  • 仅3项研究报告了IBMFRS结果,12个月时IBMFRS合并变化为-2.189分(-3.893,-0.485)(量表范围0至40分)(P=0.012),异质性相对较高。

关键数值与推荐

  • 肌力平均效应量-0.398(95%CI -0.652,-0.144)(P=0.002)。
  • SMD每周变化-0.009(-0.016,-0.002)分(P=0.015)。
  • 12个月IBMFRS合并变化-2.189分(95%CI -3.893,-0.485)(0至40分量表)(P=0.012)。
  • 徒手肌力测试异质性I2=67.68%,定量肌力测试异质性I2=0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仅3项研究报告了IBMFRS结果。
  • IBMFRS合并变化异质性相对较高。
  • 徒手肌力测试的异质性较高(I2=67.68%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: IBM is characterized by slowly progressive muscle weakness making it challenging to detect significant changes in weakness during a clinical trial. Trial participants receiving placebo may behave differently from in natural history studies. We aimed to quantify the change in muscle strength and IBM Functional Rating Scale (IBMFRS) of IBM patients receiving placebo during clinical trials. METHODS: Several databases were searched. Randomized, double-blinded, placebo-controlled trials without treatment intervention on the placebo group were included. Standardized mean differences (SMD) for change in muscle strength and mean differences for IBMFRS were used to calculate pooled effects, using DerSimonian-Laird continuous random effect models. Meta-regression determined change in muscle strength. Heterogeneity was evaluated using the I2 indicator. RESULTS: Eleven eligible trials were identified with 257 participants receiving placebo and a low risk of bias per the Cochrane Collaboration Risk of Bias 2 (RoB2) tool. Participants receiving placebo on average had a measurable decline in muscle strength with a mean effect size of -0.398 (95% CI -0.652, -0.144) (P = 0.002). SMD changed by -0.009 (-0.016, -0.002) points per week (P = 0.015). Manual muscle testing was associated with higher heterogeneity (I2 = 67.68%) compared with quantitative muscle testing (I2 = 0%). Only three studies reported IBMFRS results. The pooled change in IBMFRS at 12 months was -2.189 points (-3.893, -0.485) on this 0 to 40-point scale (P = 0.012), with relatively high heterogeneity. CONCLUSION: Participants with IBM displayed a measurable decline in their muscle strength and IBMFRS during clinical trials, in keeping with the disease's slowly progressive nature. These estimates can inform sample size calculations in future studies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Naddaf E, Skolka MP, Prokop L, et al. A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis. Rheumatology (Oxford). 2025. PMID: 40085004. doi:10.1093/rheumatology/keaf146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。